NasdaqGS - Delayed Quote USD

Vertex Pharmaceuticals Incorporated (VRTX)

397.48 -0.22 (-0.06%)
At close: April 26 at 4:00 PM EDT
397.42 -0.06 (-0.02%)
After hours: April 26 at 6:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,869,200.00
9,869,200.00
8,930,700.00
7,574,400.00
6,205,700.00
Cost of Revenue
1,262,200.00
1,262,200.00
1,080,300.00
904,200.00
736,300.00
Gross Profit
8,607,000.00
8,607,000.00
7,850,400.00
6,670,200.00
5,469,400.00
Operating Expense
4,299,500.00
4,299,500.00
3,485,000.00
2,777,900.00
2,600,000.00
Operating Income
4,307,500.00
4,307,500.00
4,365,400.00
3,892,300.00
2,869,400.00
Net Non Operating Interest Income Expense
570,600.00
570,600.00
89,800.00
-56,600.00
-36,000.00
Other Income Expense
-498,300.00
-498,300.00
-222,800.00
-1,105,300.00
283,500.00
Pretax Income
4,379,800.00
4,379,800.00
4,232,400.00
2,730,400.00
3,116,900.00
Tax Provision
760,200.00
760,200.00
910,400.00
388,300.00
405,200.00
Net Income Common Stockholders
3,619,600.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Diluted NI Available to Com Stockholders
3,619,600.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Basic EPS
14.05
14.05
12.97
9.09
10.44
Diluted EPS
13.89
13.89
12.82
9.01
10.29
Basic Average Shares
257,700.00
257,700.00
256,100.00
257,700.00
259,841.00
Diluted Average Shares
260,500.00
260,500.00
259,100.00
259,900.00
263,396.00
Total Operating Income as Reported
3,832,000.00
3,832,000.00
4,307,400.00
2,782,100.00
2,856,300.00
Total Expenses
5,561,700.00
5,561,700.00
4,565,300.00
3,682,100.00
3,336,300.00
Net Income from Continuing & Discontinued Operation
3,619,600.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Normalized Income
4,012,363.00
4,012,363.00
3,367,530.00
3,294,651.60
2,723,097.00
Interest Income
614,700.00
614,700.00
144,600.00
4,900.00
22,200.00
Interest Expense
44,100.00
44,100.00
54,800.00
61,500.00
58,200.00
Net Interest Income
570,600.00
570,600.00
89,800.00
-56,600.00
-36,000.00
EBIT
4,423,900.00
4,423,900.00
4,287,200.00
2,791,900.00
3,175,100.00
EBITDA
4,605,200.00
4,605,200.00
4,435,500.00
2,917,500.00
3,284,600.00
Reconciled Cost of Revenue
1,262,200.00
1,262,200.00
1,080,300.00
904,200.00
736,300.00
Reconciled Depreciation
181,300.00
181,300.00
148,300.00
125,600.00
109,500.00
Net Income from Continuing Operation Net Minority Interest
3,619,600.00
3,619,600.00
3,322,000.00
2,342,100.00
2,711,700.00
Total Unusual Items Excluding Goodwill
-475,500.00
-475,500.00
-58,000.00
-1,110,200.00
-13,100.00
Total Unusual Items
-475,500.00
-475,500.00
-58,000.00
-1,110,200.00
-13,100.00
Normalized EBITDA
5,080,700.00
5,080,700.00
4,493,500.00
4,027,700.00
3,297,700.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-82,737.00
-82,737.00
-12,470.00
-157,648.40
-1,703.00
12/31/2020 - 7/24/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
NVO Novo Nordisk A/S
126.85
+0.84%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
 
MRNA Moderna, Inc.
107.97
+1.69%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%